Trial of TRC105 and Sorafenib in Patients With HCC

NCT02560779 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Carotuximab (TRC105)
DRUG: Sorafenib

Sponsor

Tracon Pharmaceuticals Inc.